Navigation Links
Rash in Medical Technology

June 2009 Mayo Clinic Women's HealthSource Highlights Summer Skin Problems, Low Vision and Pilates

... treat common summer skin problems. Heat rash (miliaria rubra ) : Heat rash occurs when sweat ducts become plugged and trap perspiration beneath the skin. The rash appears as clusters of red spots or small, ...

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

... 18% in CAPACITY 2 and 38% vs. 16% in CAPACITY 1), rash (31% vs. 10% and 34% vs. 13%), fatigue (28% vs. ... and dizziness (19% vs. 10% and 18% vs. 10%). rash was generally mild to moderate in both studies; ... adverse events were as follows: IPF (2.9/2.6); rash (1.4/0); nausea (1.4/0); bladder cancer (0.9/0); ...

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY

... at the AACR and ESMO conferences, combined with rash being reported independent of the KRAS status of ... anti-EGFR antibodies, particularly severe skin rash and hypomagnesemia, were the result of properties ... radiation dermatitis have been described, severe rash has not been observed and reports of the other ...

Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia

... reported adverse reactions (>10%) were rash (33%), pruritus (29%), nausea (31%), fatigue ... reported adverse reactions ( > 10%) were rash (28%), pruritus (20%), and constipation (18%). ... (43%-57%), musculoskeletal pain (38%-49%), and rash and related terms (36%-47%)*+. ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... (43%-57%), musculoskeletal pain (38%-49%) and rash and related terms (36%-47%)*(A). ... reported adverse reactions (>10%) were rash (33%), pruritus (29%), nausea (31%), fatigue ... reported adverse reactions (>10%) were rash (28%), pruritus (20%) and constipation (18%). The ...

CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma

... assessing the relationship of rash and PFS was performed and showed a trend toward ... PFS in patients that developed Grade 2 or higher rash (n=13). Other adverse events included fatigue, ... suggest a correlation between the development of rash and clinical efficacy is very intriguing and we ...

Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults

... both treatment arms, grade 2-4 treatment-related rash occurred infrequently; three percent in the ... of treatment. Cases of severe skin rash (0.4 percent) and Stevens-Johnson syndrome (<0.1 ... receiving PREZISTA. In clinical trials (n=3063), rash (all grades, generally ...

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

... (43%-57%), musculoskeletal pain (38%-49%) and rash and related terms (36%-47%).(+)(++) The overall ... fatigue, peripheral edema, anemia, pruritus, rash and lower respiratory tract infection. All ... fatigue (48%; 53%), abdominal pain (40%; 37%), rash and related terms (38%; 53%), vomiting (38%; ...

New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy

... in the INTELENCE arm vs. placebo arm were rash of any type (22 percent vs. 11 percent), diarrhea ... were diarrhea (22.0 percent vs. 22.6 percent), rash of any type (16.6 percent vs. 11.1 percent) and ... and appropriate therapy initiated if severe rash develops -- In general, in clinical ...

European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection

... potential harm to the fetus. Mild-to-moderate rash is a common side effect of efavirenz. ... treated with efavirenz experienced new-onset skin rash compared with 17% of patients treated in control ... be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal ...

Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe

... harm to the fetus. Mild-to-moderate rash is a common side effect of efavirenz. ... treated with efavirenz experienced new-onset skin rash compared with 17% of patients treated in control ... be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal ...

New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer

... in patients receiving ERBITUX therapy. Acneform rash occurred in 76-88% of 1373 patients receiving ERBITUX in clinical trials with severe acneform rash occurring in 1-17% of patients. Acneform rash usually developed within the first two weeks of ...

European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)

... potential harm to the fetus. Mild-to-moderate rash is a common side effect of efavirenz. ... treated with efavirenz experienced new-onset skin rash compared with 17% of patients treated in control ... be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal ...

Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV

... potential harm to the fetus. Mild-to-moderate rash is a common side effect of efavirenz. ... treated with efavirenz experienced new-onset skin rash compared with 17% of patients treated in control ... be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal ...

Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA

... in patients receiving APTIVUS/r. In some, rash was accompanied by joint pain or stiffness, ... pruritus. In controlled clinical trials, rash (all grades, all causality) was observed in ... of treatment. The median time to onset of rash was 53 days and the median duration ...

Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer

... in patients receiving ERBITUX therapy. Acneform rash occurred in 76-88% of 1373 patients receiving ERBIUTX in clinical trials. Severe acneform rash occurred in 1-17% of patients. Acneform rash usually developed within the first two weeks of ...

New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy

... arm vs. 2.9 percent in the lopinavir/r arm. rash was 2.6 percent in the PREZISTA/r arm vs. 1.2 ... with PREZISTA; discontinuation due to rash was 0.3 percent. Rashes were generally ... PREZISTA should be discontinued if severe rash develops. PREZISTA should be used with caution ...

ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

... In 208 patients receiving ERBITUX + RT, acneform rash was reported in 87% (17% severe) as compared to ... ERBITUX alone, 76% (N=103) experienced acneform rash (1% severe). In patients with mCRC, acneform rash was reported in 89% (686/774) of all treated ...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

... fevers chills stomach discomfort skin rash If you take SIMPONI(TM) or other TNF blockers, your ... lupus-like symptoms. Tell your doctor if you have any symptoms such as a rash on your cheeks or other parts of the body, sensitivity to the sun, new ...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

... fevers chills stomach discomfort skin rash If you take SIMPONI(TM) or other TNF blockers, your risk ... lupus-like symptoms. Tell your doctor if you have any symptoms such as a rash on your cheeks or other parts of the body, sensitivity to the sun, new ...

New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease

... of HBV - feeling unwell, poor appetite, tiredness, fever, skin rash and/or joint pain. Liver injury - jaundice (yellow skin and eyes), ... discomfort or pain that does not go away, shortness of breath, joint pain, rash on the cheeks or arms that gets worse in the sun. The more common side ...

CuraGen Updates CR011-vcMMAE Data at ASCO

... Grade 3 or 4 neutropenia was observed in 5 patients. The absence of rash in the first cycle of treatment predicted a worse PFS. Additionally, in a ... dose, schedule and the use of biomarkers such as the presence of GPNMB and rash might be used to enhance activity in further development." Reprints ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... (23%-58%), diarrhea (43%-57%), musculoskeletal pain (38%-49%), and rash and related terms (36%-47%).*(+) The adverse reactions and safety ... 58%), diarrhea (59%; 70%), fatigue (48%; 53%), abdominal pain (40%; 37%), rash and related terms (38%; 53%), vomiting (38%; 35%), musculoskeletal pain ...

Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

... commonly occurring adverse events were upper respiratory tract infections, rash and urinary tract infections. A pooled analysis of the safety data show ... pyrexia (3% CIMZIA, 2% placebo), pharyngitis (3% CIMZIA, 1% placebo), rash (3% CIMZIA, 1% placebo), acute bronchitis (3% CIMZIA,1% placebo), fatigue ...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

... mg once-daily cohort and one in the 600 mg bid cohort) developed grade 2 rash and discontinued treatment after either six or seven days of consecutive dosing. There were no other instances of rash in this or any other study of ANA598. Data receipt and analysis from this ...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

... anorexia (20% vs 22%), dyspnea (15% vs 23%), HFS (51% vs 1%), and rash (29% vs 12%) - In addition, 19% vs 52.3% reported alopecia (all ... peripheral neuropathy (42% vs 45%), neuralgia (17% vs 20%), and rash (22% vs 18%) - In addition, 19% vs <1% reported HFS * In ...

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

... and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) ... cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness ...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

... and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) ... cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness ...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

... and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) ... cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness ...

U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant

... and muscle pain, nausea and vomiting. A few days after fever onset, a rash often develops over most of the body and lasts for one to two days. The rash can reappear several days later. These symptoms typically begin within a ...

RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors

... adverse events in patients taking RAD001 alone were stomatitis (44%), rash (40%), diarrhea (37%), fatigue (29%), nausea (26%), vomiting (17%), ... patients taking RAD001 with Sandostatin LAR Depot were stomatitis (49%), rash (40%), diarrhea (29%), fatigue (33%), nausea (33%), vomiting (13%), ...

New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients

... cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness ... and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) ...

Shingles Pain Treatment Will Benefit More Patients

... that persists for more than three months after the onset of the shingles rash is called Post-herpetic Neuralgia (PHN) (2). PHN affects approximately ... pain. The pain can start several weeks or even months after the shingles rash has gone and can continue for weeks, months or years(4). Licensed in the ...

FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)

... hypotension (50%), back pain (30%), dyspnea (28%), vasodilation (28%), rash (25%), chest pain or tightness (24%), tachycardia (12%), dysphagia or ... (48%), pain (48%), edema (47%), hypotension (36%), anorexia (36%), and rash (34%). Post-Marketing: The following adverse reactions have been ...

June 2008 Mayo Clinic Women's HealthSource Highlights Shingles Vaccine for Pain Prevention, Tips to Avoid Antibiotic Resistant Infections, and Benefits of Broad Genetic Testing

... Vaccine A vaccine to prevent shingles -- a painful and common skin rash -- has been available for more than two years, but few people reportedly ... over 60 develop shingles. Shingles usually appears as a blistering rash along one side of the trunk, chest, back or face. The condition is ...

Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting

... phase patients, the most commonly reported adverse reactions ( >10%) were rash (33%), pruritus (29%), nausea (31%), fatigue (28%), headache (31%), ... phase patients, the most commonly reported adverse reactions ( >10%) were rash (28%), pruritus (20%), and constipation (18%). The most common ( >10%) ...

CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients

... respectively), jaundice (four percent and zero percent, respectively) and rash (three percent and two percent, respectively). The REYATAZ/r arm was ... in bilirubin levels in the blood (bilirubin is made by the liver). * rash (redness and itching) sometimes occurs in patients taking REYATAZ, ...

Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration

... in seven percent of subjects treated with PREZISTA; discontinuation due to rash was 0.3 percent. Rashes were generally mild-to-moderate, self-limiting and maculopapular. PREZISTA should be discontinued if severe rash develops. PREZISTA should be used with caution in patients with known ...

FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent

... pill included dizziness, flu-like symptoms, diarrhea, cough, and tiredness. Other less common reactions to TEKTURNA and TEKTURNA HCT include skin rash and, additionally with TEKTURNA, cough. Disclaimer The foregoing release contains forward-looking statements that can be ...

New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed

... The 14-day lead-in period is important because it can help reduce your chances of getting a potentially serious skin rash. Patients who have a skin rash during the first 14 days should immediately contact their HCP and not increase their VIRAMUNE dose to twice a day. The total duration of the ...
Other Contents
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
(Date:4/26/2015)... Italian public health researchers have released new data ... and other asbestos-related industries. Surviving Mesothelioma has just posted ... to read it now. , University researchers ... Medicine analyzed more than 15,000 cases of mesothelioma between ... asbestos cancer was most common. , “Asbestos cement ...
(Date:4/26/2015)... (PRWEB) April 26, 2015 From March ... and his wife, Trivedi Master™ Dahryn Trivedi, spent a ... approved research laboratories and institutions in the efforts of ... medicine and nutraceutical supplements for human health care. ... different research labs and institutions. All lab facilities are ...
(Date:4/26/2015)... Rosa, CA (PRWEB) April 26, 2015 In ... from Washington State University evaluated the head-neck biomechanics occurring during ... of the study were able to determine that use of ... much as 3 to 5 times - more than when ... surprising outcome for such a study, but pointing out the ...
(Date:4/25/2015)... April 26, 2015 The National ... , a national endeavor to prepare nurses to provide ... a great success, according to a new report by ... original funding partners. , The project began in ... (CCP), under the direction of Elaine Tagliareni, EdD, RN, ...
(Date:4/25/2015)... The Hon. Ellen Tauscher, Independent Chair of the ... following the deadly earthquake in Nepal: , "Today a ... deaths of more than 1,000 people. The aftershocks ... India and other parts of South Asia. I ... of Nepal and the families of the victims. ...
Breaking Medicine News(10 mins):Health News:New Investigation Finds Mesothelioma “Clusters” Around Italian Cement Plants, According to Surviving Mesothelioma 2Health News:Trivedi Science™ Has Started Scientific Research to Create More Effective Pharmaceuticals and Nutraceuticals 2Health News:Trivedi Science™ Has Started Scientific Research to Create More Effective Pharmaceuticals and Nutraceuticals 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 3
Other TagsOther Tags